A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

This study is evaluating a treatment for primary vitreoretinal lymphoma — a rare cancer that affects the jelly-like fluid (vitreous) inside the eye and the retina. The study involves injecting a chemotherapy drug (methotrexate) directly into the eye. **You may be eligible if...** - You are 21 years old or older - You have been diagnosed with primary vitreoretinal lymphoma confirmed by biopsy - Cancer cells are present in the vitreous fluid of your eye at the screening visit **You may NOT be eligible if...** - You are allergic to methotrexate - You are planning to have eye surgery during the trial - You are pregnant or breastfeeding (if you are a woman of childbearing age) - You have other eye conditions that could interfere with the study - You received systemic methotrexate within one week before starting the trial Talk to your doctor to see if this trial is right for you.